In these annotated PowerPoints I discuss the control of diabetes in the perioperative period in patients taking insulin. Please download these slides and view them in PowerPoint so you can view the annotations describing each slide.
DM is a metabolic disorder with an increasing global incidence and prevalence. Poor peri-operative glycaemic control increases the risk of adverse outcomes. Through careful glycemic management in perioperative period, we may reduce morbidity and mortality and improve surgical outcomes.
DM is a metabolic disorder with an increasing global incidence and prevalence. Poor peri-operative glycaemic control increases the risk of adverse outcomes. Through careful glycemic management in perioperative period, we may reduce morbidity and mortality and improve surgical outcomes.
Perioperative management of a patient with diabetes mellitusrajkumarsrihari
Anesthetic implications in a patient with Diabetes Mellitis with latest updates taken from british journal of anesthesia on perioperative glycemic control (2013)
Perioperative management of diabetes mellitusSourav Mondal
A detailed stepwise approach for the perioperative management of diabetes mellitus.
Sources taken from latest edition of Harrison, Millers, Stoeltings and ADA Guidelines.
By a anaesthetist, for a anaesthesist
Hypothyroidism and hyperthyroidism have significant clinical effects. Both should be optimized. Anesthesia providers should be able to diagnose and manage.
In these powerpoints I describe how to control glycemia in the perioperative period in patient with diabetes not taking insulin. Please download these slides and view them in PowerPoint so you can view the annotations describing each slide.
Perioperative management of a patient with diabetes mellitusrajkumarsrihari
Anesthetic implications in a patient with Diabetes Mellitis with latest updates taken from british journal of anesthesia on perioperative glycemic control (2013)
Perioperative management of diabetes mellitusSourav Mondal
A detailed stepwise approach for the perioperative management of diabetes mellitus.
Sources taken from latest edition of Harrison, Millers, Stoeltings and ADA Guidelines.
By a anaesthetist, for a anaesthesist
Hypothyroidism and hyperthyroidism have significant clinical effects. Both should be optimized. Anesthesia providers should be able to diagnose and manage.
In these powerpoints I describe how to control glycemia in the perioperative period in patient with diabetes not taking insulin. Please download these slides and view them in PowerPoint so you can view the annotations describing each slide.
Human insulin is a key drug to treat hyperglycemic conditions in ED, so how well we understand the most common Intravenous Insulin Protocol - "The Portland Protocol" !! Lets brush up a bit of most common Portland protocol which is used frequently in DKA and other hyperglycemic states in ED and the ICUs.
Perioperative management of patients on corticosteroidsTerry Shaneyfelt
In these annotated PowerPoints I discuss the evaluation and perioperative management of patient taking or who have taken steroids. I discuss how to determine if the adrenal axis is suppressed and how to provide supplemental glucocorticoids if needed. Remember to download these slides to see the annotations for each slide.
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal SurgeryTerry Shaneyfelt
In these annotated PowerPoint slides I describe the perioperative evaluation and management of patients with hypothyroidism needing nonthyroid surgery. Remember to download these slides to view the annotations for each slide.
Preoperative evaluation of patients with diabetesTerry Shaneyfelt
In these annotated slides I discuss the things you need to consider in the preoperative evaluation of patients with diabetes. This sets the stage for perioperative management of diabetes. Please download these slides and view them in PowerPoint so you can view the annotations describing each slide.
These annotated slides will help you interpret an OR or RR in clinical terms. Please download these slides and view them in PowerPoint so you can view the annotations describing each slide.
Preoperative evaluation of adults with sleep apneaTerry Shaneyfelt
Patients with sleep apnea present unique challenges in the perioperative period. Over half of patients with sleep apnea are undiagnosed at the time of surgery. I review how to assess risk in patients with suspected or confirmed sleep apnea.
Gupta indices for postop pulmonary complicationsTerry Shaneyfelt
Gupta and colleagues developed 2 prediction rules that can be used to estimate a patient's risk for postoperative pneumonia or respiratory failure. I also review an older prediction rule and show how it compares to the Gupta rules.
In these slides I discuss what to do with the patient post stent who needs noncardiac surgery and I discuss what to do with anti-platelet therapy in the perioperative period. Watch my YouTube description of these slides at http://youtu.be/z8Okm3_GFbU.
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?Terry Shaneyfelt
Review of the effect of beta blockers on perioperative cardiac events including updated recommendations by the ACC/AHA (August 2014. Watch my YouTube video (http://youtu.be/WPLXDm9Nzoc) describing these slides.
Review of 2 metaanalyses of RCTs on the effects of statins in the perioperative period. Watch my YouTube video describing these slides: http://youtu.be/wHYlf26AH00
Who needs preoperative noninvasive cardiac testingTerry Shaneyfelt
Review of recommendations on noninvasive cardiac testing prior to noncardiac surgery. Watch my YouTube video describing these slides: http://youtu.be/lDRUrx45pMw
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Perioperative Diabetes Management in Patients on Insulin
1. Perioperative Diabetes Management:
Insulin
Terry Shaneyfelt, MD, MPH
Assoc. Professor, UAB Department of Medicine
The information contained in these slides is for educational purposes only and not meant to guide clinical care. Please refer to
package inserts and guidelines for prescribing information.
2. There is little evidence on the optimal
perioperative management of diabetes
3. Goals of glycemic control
1. Avoid hypoglycemia
2. Prevent ketoacidosis and hyperosmolar states
3. Maintain fluid and electrolyte balance
4. Avoid marked hyperglycemia
• Optimal perioperative glycemic targets unclear:
• ADA: fasting <140 mg/dl for general hospitalized
patients (random < 180 mg/dl)
• CDA: Perioperative glycemic levels should be
maintained between 90-180 mg/dl
4. Perioperative glycemia management
• No consensus on optimal management strategy to
maintain target glucose levels
• Surgery should be scheduled as early as possible
in the morning to minimize NPO time
5. Short Procedures (< 2hrs)
• Minor, early morning procedure
• Delay usual morning short or rapid acting insulin until
postop and right before eating
• Long acting insulin or insulin pump: continue usual basal
insulin
6. Short Procedures (< 2hrs)
• Late morning or early afternoon procedure
• Omit morning short or rapid acting insulin
• AM mixed insulin (Intermediate insulin or long + rapid
acting)
• 1/2 - 2/3 of usual total morning dose as NPH or long acting
• BID mixed insulin
• 1/3-1/2 of usual total morning dose as NPH or long acting
• Insulin pump: continue basal infusion rate
• D5W or D5 1/2NS @ 75-125 cc/hr
• Check hourly blood sugar
• Correction short acting insulin for hyperglycemia
7. Long and complex procedures
• IV insulin preferred
• Short half life (5-10 min)- more precise titration
• Less variable glucose vs SQ route
• Begin insulin infusion prior to surgery to achieve
glycemic control
• Glucose is also needed
• GIK infusion- start 100cc/hr & titrate
• Separate insulin and glucose IV solutions (5-10 gm/hr)
8. Long and complex procedures
• Initial insulin infusion rate (U/hr)
• Blood glucose level ÷ 100
• Check glucose levels Q 1-2 hrs
• Titrate insulin infusion
• 120-160 mg/dl: increase by 0.5 U/hr
• 160-200 mg/dl: increase by 1 U/hr
• >200 mg/dl: increase by 2 U/hr
• Never d/c insulin in type 1 diabetes
9. Postop treatment
• Once the patient is eating well resume preop
regimen
• Insulin infusion
• 1st dose of SQ insulin must be given before stopping IV
• Intermediate or long acting: 2-3 hrs prior to stopping IV insulin
• Short or rapid acting: 1-2 hrs prior to stopping IV insulin
• If not eating well continue IV dextrose (5-10
gm/hr)
10. Knowledge Check
• You are asked to see a 67 yo M with type 2 DM in the
1 day prior to CABG. He uses 70/30 insulin 40U in
the am and 30U in the pm as an outpt. Last A1C
7.5%. Glucose 1 hour ago was 188 mg/dl. What do
you recommend?
A. Cont usual dose of 70/30 today and give 20 U NPH the morning of the
procedure
B. Usual home dose of 70/30 insulin with frequent glucose checks
C. Begin glucose & insulin infusion today at an initial rate of 2 U/hr
D. Begin glucose & insulin infusion early in the morning prior to surgery at an
initial rate of 2 U/hr
E. Convert to glargine 40U SQ on the morning of surgery
Editor's Notes
These PowerPoints will review glycemia management during the perioperative period in diabetic patients on insulin.
There is little evidence to guide the optimal management of diabetes in the perioperative period. Some is extrapolated from studies of the management of hospitalized patients with diabetes. Much of it is opinion.
There are 4 broad goals of glycemic control in the perioperative period: avoid hypoglycemia, avoid marked hyperglycemia, avoid ketoacidosis, and maintain fluid and electrolyte balance.
The optimal perioperative glycemic targets are unclear and based on opinion (Canadian guidelines) or based upon goals for hospitalized patients in general (ADA).
Opinions vary as how to best maintain blood glucose in the target range.
Surgery should be scheduled in early morning to minimize NPO time and to minimize disruption of the management routine.
For minor early morning procedures in which breakfast is only delayed patients can continue their usual long acting insulin but should delay short or rapid acting insulin until after surgery right before eating.
For procedures that are later in the morning or early afternoon (in which both breakfast and lunch are missed or delayed) should follow the recommendations on this slide. I personally use the ½ of total am dose as NPH as this is easy to remember. Don’t forget to give some glucose as either D5W or D5 1/2NS to provide some glucose. Check blood sugars hourly and if hyperglycemia develops give correction insulin
For long complex procedures an insulin infusion is preferred. IV insulin has a short half life and allows for more precise titration. It also is predictably absorbed and thus results in less variable glucose levels vs the SQ route.
The insulin infusion should be begun prior to surgery to achieve a steady state glycemic control.
Glucose is also needed. It is supplied as a GIK infusion (glucose-insulin-potassium) or as separate insulin and glucose infusions. GIK is somewhat harder to titrate as it comes with premixed concentrations of insulin (usually 15U in 500 cc dextrose).
To determine the initial insulin infusion rate divide the blood glucose level by 100 yielding the units/hour to be infused. For example, if the blood glucose is 300 mg/dl then start infusing 3 U of insulin per hour. Glucose should be checked every 1 to 2 hours. If the desired blood glucose is not achieved then titrate by the suggested scale above.
If hypoglycemia developed reduce insulin infusion rate by 0.5 U/hr. Importantly, never stop insulin in type 1 diabetics to avoid ketosis.
Once the patient is eating well they can resume their preop regimen. If the patient was on an insulin infusion the first SQ dose must be given prior to discontinuing the IV insulin. Intermediate or long acting insulin is given 2-3 hrs prior to stopping the IV whereas short or rapid acting insulin is given 1-2 hrs prior to stopping the insulin infusion. If the patient is not eating well continue the IV dextrose infusion.
A is incorrect because the patient is undergoing a complex procedure. This would be reasonable for minor procedure.
B is incorrect because insulin requirements will change drastically with CABG and this regimen would be hard to titrate.
C is incorrect because the insulin infusion would not need to be started so soon. The patient can continue his home regimen the night prior to surgery then start the IV insulin early on the morning of surgery.
D is correct. An insulin infusion will be needed for this complex procedure and should be started early on the morning of surgery.
E is incorrect because this patient is undergoing a complex procedure and glargine would be difficult to titrate as it is long acting.